#DIA22: Fire­side chat with Zachary Bren­nan and Aaron Kessel­heim

Zachary Bren­nan:

Hi, good af­ter­noon. Wel­come to End­points DIA 2020. We are joined at this af­ter­noon’s fire­side chat with a spe­cial guest, Har­vard Pro­fes­sor of Med­i­cine, Aaron Kessel­heim. If you fol­low the FDA close­ly, you’ve prob­a­bly come across Aaron’s re­search fre­quent­ly, but I want­ed to be­gin to­day’s dis­cus­sion be­cause I think a lot of the rea­son we’re talk­ing about ac­cel­er­at­ed ap­proval re­forms and FDA re­forms over the next five years are linked to a re­cent­ly ap­proved drug that has been very con­tro­ver­sial, known as Bio­gen’s Aduhelm, which is a treat­ment for Alzheimer’s dis­ease.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN